Does Retatrutide Cause Cancer? What the Data Can and Can't Say

Written by Olha Orlyk. Updated November 2, 2026.

There is no evidence that retatrutide causes cancer, but the evidence is also too limited to rule it out. In the published phase 2 trial, 338 people were followed for 48 weeks and no cases of medullary thyroid cancer or thyroid C-cell overgrowth were reported; one kidney cancer occurred on retatrutide and was judged unrelated by the investigators. Lilly's phase 3 announcements, covering more than 5,000 participants for up to 80 weeks, have not reported a cancer signal, but full cancer counts have not been made widely available, and trials of this length cannot detect rare cancers that take years to develop. Retatrutide belongs to the same family as semaglutide and tirzepatide, which carry a boxed warning because they caused thyroid tumours in rodents; human studies of those drugs are mixed, with a 2025 analysis of 48 trials finding no significant increase in thyroid or pancreatic cancer. Retatrutide is not approved anywhere. This guide sets out what the trials have reported, what is known from related drugs, and what cannot be known yet.

A press release is not a safety report, so the absence of cancer from these announcements is not the same as the absence of cancer in the trials. Full journal papers and, eventually, the FDA's review will give detailed counts. The phase 2 trial is currently the only one whose cancer findings we could verify in full. Results of the newer trials are summarised in TRIUMPH-2 and TRIUMPH-3 results and in retatrutide news.

In the published phase 2 trial, no cases of medullary thyroid cancer or C-cell hyperplasia were reported. That trial also screened out people with high calcitonin, a blood marker of C-cell activity, and people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2). Some websites report thyroid findings from the TRIUMPH-1 paper; we have not been able to verify those figures against the paper itself, so we do not repeat them here. Thyroid cancer is rare, and trials of this size and length are not designed to detect small changes in its risk.

Wegovy (semaglutide) and Zepbound (tirzepatide) both carry a boxed warning because in rodents they caused tumours of the thyroid's C-cells, which make calcitonin, at exposures relevant to human doses. Rodent C-cells have many more GLP-1 receptors than human C-cells, and whether the finding applies to people has not been determined. As a precaution, both drugs are contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Retatrutide also activates the GLP-1 receptor, as explained in what is GLP-3 RT, so a similar warning would be expected if it is approved; no retatrutide rodent cancer study has been published.

Taken together, these studies suggest that if GLP-1 drugs raise thyroid cancer risk at all, the absolute increase is small, and part of the signal in some studies may come from more thyroid scans and blood tests in people on these drugs, which find small cancers that would otherwise go unnoticed. None of these studies included retatrutide.

Early concerns about pancreatic cancer with GLP-1 drugs have not been borne out. The 2025 meta-analysis of 48 trials found no increase (odds ratio 0.84), and a large Israeli cohort of more than 540,000 adults with type 2 diabetes found no raised risk over five to seven years compared with insulin. Pancreatitis, inflammation of the pancreas, is a separate known risk: one case occurred on the highest dose in the retatrutide phase 2 trial.

Obesity raises the risk of at least 13 types of cancer, so substantial weight loss could, in principle, lower it. In a 2024 study of US health records from people with type 2 diabetes, GLP-1 drugs were linked to lower risk of 10 of 13 obesity-related cancers compared with insulin, though not compared with metformin, and to a higher risk of kidney cancer compared with metformin. These are observational findings and cannot prove cause and effect. In mouse studies, retatrutide slowed the growth of pancreatic and lung tumours linked to obesity, but mouse results often do not translate to people. Retatrutide is not a cancer treatment.

Retatrutide is the first drug in its class to also activate the glucagon receptor. We found no evidence that glucagon receptor activation promotes cancer in people, and no published study has raised it as a specific risk. It is fair to say only that this is a new combination of mechanisms, with no long-term human data yet, which is why post-approval monitoring will matter. How retatrutide differs from tirzepatide is covered in retatrutide vs tirzepatide.

Most cancers develop over many years, and trials lasting 40 to 80 weeks with a few thousand participants can detect common side effects but not small increases in rare cancers. Trials also exclude people at higher risk, such as those with a history of certain cancers. Questions like this are usually answered by large observational studies after a drug has been used by many people for years, as happened with semaglutide. Retatrutide's other side effects, such as skin sensitivity, are better characterised; see retatrutide dysesthesia.

Yes, for reasons unrelated to the molecule itself. Lilly says retatrutide is not approved and that illicit products may contain unknown ingredients, contaminants and impurities. The FDA has issued warning letters to sellers of 'research use only' retatrutide, treating it as an unapproved drug, and an advocacy group reported at least 14 hospitalizations linked to such products. None of the trial safety data apply to products of unknown content. Lilly plans to file for approval in the first quarter of 2027, as tracked in when will retatrutide be approved; until then, the only legitimate access is through a clinical trial, as explained in how to get retatrutide.

So far, retatrutide has not been shown to cause cancer: the phase 2 trial found no thyroid cancer, and the phase 3 announcements have reported no cancer signal. But trials of this length cannot rule out rare or slow-developing cancers, full cancer data from phase 3 are still emerging, and the drug is not approved. Related GLP-1 drugs carry a rodent-based thyroid warning, while large human studies have mostly been reassuring. For a balanced view of what retatrutide does offer, see retatrutide benefits and what is retatrutide.

Retatrutide is an investigational drug and is not approved for any use. This article summarizes published research for general information and is not medical advice.